SIGACHISigachi Industries Limited
Convert to ideaHealthcare · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 1.1 this quarter.
Momentum from moving averages, Supertrend and RSI.
2 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
2 found · risk minor
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹130 Cr | ₹9 Cr | 11.27% | 6.73% | ₹0.27 | 3.9x |
| Q1 FY2027 | ₹121 Cr | ₹8 Cr | 9.98% | 6.71% | ₹0.18 | 4.3x |
| Q4 FY2026 | ₹122 Cr | ₹8 Cr | 9.71% | 6.27% | ₹0.20 | 2.8x |
| Q3 FY2026 | ₹117 Cr | ₹-0 Cr | 1.30% | -0.01% | ₹0.01 | 0.4x |
| Q2 FY2026 | ₹110 Cr | ₹11 Cr | 3.10% | 9.53% | ₹0.28 | 3.4x |
| Q1 FY2026 | ₹128 Cr | ₹-101 Cr | 15.10% | -78.74% | ₹-2.63 | -29.6x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.